

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number
WO 03/080801 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US03/08582

(22) International Filing Date: 19 March 2003 (19.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/365,498 19 March 2002 (19.03.2002) US

(71) Applicant: **ADVANCED RESEARCH & TECHNOLOGY TRANSFER** [US/US]; 351 West 10th Street, Indianapolis, IN 46202 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: **MARCH, Keith, L.**; 13800 Oakwood Court, Carmel, IN 46032 (US). **REHMAN, Jalees**; 6317 Mosport Court, Apt. B, Indianapolis, IN 46224 (US).

Published:
— *without international search report and to be republished upon receipt of that report*

(74) Agents: **RIGAUT, Kathleen, D.** et al.; Dann, Dorfman, Herrell and Skillman, 1601 Market Street, Suite 720, Philadelphia, PA 19103-2307 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/080801 A2

(54) Title: ADIPOSE STROMAL STEM CELLS FOR TISSUE AND VASCULAR MODIFICATION

(57) Abstract: The present invention provides isolated adipose derived stromal cells and methods of use thereof.

**ADIPOSE STROMAL STEM CELLS FOR TISSUE AND VASCULAR
MODIFICATION**

10 CROSS REFERENCE TO RELATED APPLICATION

This application claims priority to US provisional application 60/365,498 filed March 19, 2002, the entire disclosure of which is incorporated by reference herein.

FIELD OF THE INVENTION

The present invention relates to the fields of cardiology, vascularization, and molecular biology. More specifically, methods are provided for isolating stem cells from adipose tissue, optionally inducing the stem
20 cells to secrete endogenous or exogenously provided growth factors, and re-administering such stem cells to a patient for therapeutic benefit.

BACKGROUND OF THE INVENTION

Several publications and patent documents are cited throughout the specification in order to describe the state of the art to which this invention pertains. Each of these references is incorporated herein as though set
30 forth in full.

Coronary artery disease (CAD) is a major cause of morbidity and mortality, requiring bypass surgery or angioplasty in almost 1,000,000 patients/year in the USA. While some of these patients form collateral vessels as alternative pathways for blood supply, thus ameliorating

or preventing ischemic myocardial damage, many do not form the vascular networks to sufficiently compensate for the loss of the original blood supply. Accordingly, many patients could be helped by the development of compositions and methods which would accelerate natural processes of post-natal collateral vessel formation. Such approaches are broadly referred to as "therapeutic angiogenesis", and encompass both angiogenesis (which strictly speaking refers to capillary sprouting) and
10 arteriogenesis (the maturation and enlargement of existing vessels) (Isner JM and Asahara T. *J Clin Invest.* (1999)103:1231-6; van Royen N, et al. *Cardiovasc Res.* (2001)49:543-53.)

An emerging therapeutic approach is the use of stem and progenitor cell transplantation to improve angiogenesis. Endothelial progenitor cells (EPCs) are cells present in bone marrow or peripheral blood which co-express stem and progenitor cell markers like CD34 or AC133, as well as endothelial markers like VE-Cadherin
20 and VEGF-Receptor-2 (KDR) (Rafii S., *J Clin Invest.* (2000)105:17-9.) EPCs and hematopoietic stem cells (HSCs) are thought to be derived from a common "hemangioblast" precursor (Ribatti D, et al. *J Hematother Stem Cell Res.* (2000) 9:13-9; Choi K. *J Hematother Stem Cell Res.* (2002)11:91-101; Eichmann A, et al. *J Hematother Stem Cell Res.* (2002)11:207-14.) Interestingly, the cell surface marker CD34 is only found on either hematopoietic stem / progenitor cells or endothelial cells (Rafii S., *J Clin Invest.* (2000)105:17-9,) which may be a reflection
30 of the common origin of these two cell lineages. In addition to the shared "hemangioblastic" ancestry between HSCs and endothelial cells, HSCs have also been suggested

to trans-differentiate into either endothelial progenitor cells or mature endothelial cells (Kang HJ, et al. *Br J Haematol.* (2001)113:962-9; Quirici N, et al. *Br J Haematol.* (2001)115:186-94; Gehling UM, et al. *Blood.* (2000) 95:3106-12.) The recent discovery of circulating smooth muscle progenitor cells, and the potential of HSCs to differentiate into smooth muscle cells (Sata M, et al. *Nat Med.* (2002)8:403-9; Simper D, et al. *Circulation.* (2002)106:1199-204) may suggest yet another novel and
10 intriguing link between the hematopoietic and vascular cell lineages, now in the context of smooth muscle cells.

Animal studies using hindlimb ischemia or myocardial ischemia models in immune deficient rodents have demonstrated that transplantation of about 10^6 peripheral blood derived EPCs (Kawamoto A, et al. *Circulation.* (2001)103:634-7; Kalka C, et al. *Proc Natl Acad Sci U S A.* (2000)97:3422-7) can result in increased angiogenesis. Remarkably, labeled peripheral blood derived EPCs appear to home preferentially to ischemic
20 areas and incorporate into foci of neovascularization (Kawamoto A, et al. *Circulation.* (2001)103:634-7; Kalka C, et al. *Proc Natl Acad Sci U S A.* (2000)97:3422-7.) In addition to the above-mentioned studies on peripheral blood-derived cells, EPCs derived from bone marrow, unpurified bone marrow mononuclear cells, and HSCs have also been shown to enhance angiogenesis or show endothelial differentiation *in vivo* in a variety of animal models of ischemia (Kocher AA, et al. *Nat Med.* (2001)7:430-6; Shintani S, et al. *Circulation.* (2001)
30 103:897-903; Fuchs S, et al. *J Am Coll Cardiol.* (2001)37:1726-32; Kamihata H, et al. *Circulation.* (2001)104:1046-52; Orlic D, et al. *Proc Natl Acad Sci U S*

A. (2001)98:10344-9; Jackson KA, et al. *J Clin Invest.* (2001)107:1395-402.)

Transplantation of hematopoietic stem cells (HSCs) into patients with myelodysplastic disorders or following myeloablative radiochemotherapy is the most widespread application of stem cell therapy. HSCs are characterized by surface markers like CD34, and constitute less than 0.5-1% of the bone marrow (Gunsilius E, et al. *Biomed Pharmacother.* (2001)55:186-94,) which is currently the
10 primary source of transplantable HSCs in the clinical setting. The limited availability of HLA-compatible siblings (less than 30%) (Tabbara IA, et al. *Arch Intern Med.* (2002)162:1558-66) has resulted in frequent use of non-HLA-compatible siblings as donors. Although recently there has been some success in the reduction of complications following allogeneic transplantation of HSCs, chronic graft versus host disease and engraftment failure of allogeneic cells remains a significant clinical problem (Tabbara IA, et al. *Arch Intern Med.*
20 (2002)162:1558-66.) Autologous stem cell transplantation circumvents these complications, however, autologous cells from the bone marrow or peripheral blood may be contaminated by malignant cells (Hahn U and To LB, In: Schindhelm K, Nordon R, eds. *Ex vivo Cell Therapy*. San Diego, CA: Academic Press; (1999)99-126.)

While the concept of using autologous peripheral blood derived EPCs in patients seems attractive, based on animal studies, one would need 12 liters of blood from a patient to isolate enough cells to achieve a pro-
30 angiogenic effect (Iwaguro H, et al. *Circulation.* (2002)105:732-8.) This amount of blood is not readily available in a clinical setting. Human studies that have

used of bone marrow cell transplantation in ischemic patients (Strauer BE, et al. *Dtsch Med Wochenschr.* (2001)126:932-8; Tateishi-Yuyama E, et al. *Lancet.* (2002)360:427-435) suggest that human angiogenic cell therapy requires at least cell numbers of 10^7 to 10^9 , depending on the degree of stem cell purity as well as the optimal delivery method.

The discovery of pluripotent cells in the adipose tissue (Zuk PA, et al. *Tissue Engineering.* (2001)7:211-
10 28) has revealed a novel source of cells that may be used for autologous cell therapy to regenerate tissue. The pluripotent cells reside in the "stromal" or "non-adipocyte" fraction of the adipose tissue; they were previously considered to be pre-adipocytes, i.e. adipocyte progenitor cells, however recent data suggests a much wider differentiation potential. Zuk et al. were able to establish differentiation of such subcutaneous human adipose stromal cells (ASCs) *in vitro* into adipocytes, chondrocytes and myocytes (Zuk PA, et al.
20 *Tissue Engineering.* (2001)7:211-28.) These findings were extended in a study by Erickson et al., which showed that human ASCs could differentiate *in vivo* into chondrocytes (Erickson et al. *Biochem Biophys Res Commun.* (2002)290:763-9) following transplantation into immune-deficient mice. More recently, it was demonstrated that human ASCs were able to differentiate into neuronal cells (Safford KM, et al. *Biochem Biophys Res Commun.* (2002)294:371-9).

Given the many applications of stem cell therapy, a
30 need exists in the art for providing a more abundant and practical source for such stem cells, and for enhancing

the potential therapeutic benefit and route of administration of these cells.

SUMMARY OF THE INVENTION

In accordance with the present invention, an isolated, adipose tissue derived stromal cells are provided. The cells of the invention may be induced to express at least one characteristic of a variety of cell
10 types including but not limited to cardiac cells, endothelial cells, smooth muscle cells, dopaminergic neuronal cells, hematopoietic cells, or hepatic cells. Further, the cells may be induced to express a growth factor including but not limited to vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), granulocyte-colony stimulating factor (G-CSF), and basic fibroblast growth factor (bFGF), with or without subsequent cell culture.

Another object of the present invention is to
20 provide a method of promoting angiogenesis, cardiomyogenesis, or regeneration of hematopoietic cells in which the cells of the invention are delivered to a patient. The cells may be delivered by methods which include but are not limited to retrograde coronary venous infusion, retrograde delivery to other tissues, direct injection into target tissue, intra-arterial or intra-coronary infusion via a catheter, and systemic intravenous administration.

Another object of the invention is a method for
30 isolating adipose derived stem cells, and optionally culturing the cells in a medium of interest. As a further option, these cells may be exposed to a receptor

ligand cocktail including but not limited to at least one of VEGF, LIF, bFGF, IGF1, IGF2, HGF, cardiotrophin, myotrophin, nitric oxide synthase 3, tumor necrosis factor alpha, tumor necrosis factor beta, fibroblast growth factor, pleiotrophin, endothelin, and angiopoietin.

In yet a further embodiment of the invention, the adipose derived stromal cells may comprise an exogenous nucleic acid encoding a protein of interest.

10 BRIEF DESCRIPTIONS OF THE DRAWING

Figures 1A-B show phase contrast micrographs of sub-confluent (1A) and confluent (1B) cultures of human adipose stromal cells grown in EGM2MV media, at 250x magnification.

Figure 2 is a graph showing growth of human subcutaneous adipose stromal cells.

- 20 Figure 3 shows flow cytometric analysis of fresh human subcutaneous adipose stromal cells.

Figure 4 shows flow cytometric analysis of Sca-1 expression (green) and the corresponding isotype control (pink.)

Figure 5 shows flow cytometric analysis of CD-34 and VE-cadherin expression on plated adipose stromal cells.

- 30 Figures 6A-B show human aortic endothelial cells (6A) and human adipose stromal cells (6B) plated overnight on Matrigel.

Figure 7 shows smooth-muscle alpha-actin staining on adipose stromal cells.

Figure 8 is a graph which shows secretion of growth factors VEGF, HGF, and G-CSF, presented as mean +/- standard error of mean of pg/10⁶ cells.

Figure 9 is a micrograph of GFP expression on porcine adipose stromal cells. The fluorescent image is overlaid
10 on a phase contrast image.

Figure 10 shows flow cytometric analysis of murine adipose stromal cells gated on CD45(-) cells. The R3 cells are an ASC Sca-1(+)CD45(-)c-kit(-) population, while the R4 cells are Sca-1(-)CD45(-)c-kit(-).

Figures 11A-E show a series of micrographs (320x) taken following 12 days of culture of Sca-1(+)CD45(-)c-kit(-) cells from muscle tissue and adipose tissue, which shows
20 adipocyte-like differentiation (Oil-Red-O stain, 11A and 11D) or neuron-like differentiation (phase-contrast in 11B and 11E) when grown in the respective differentiation media. Panel 11C shows staining for the neuronal tau-protein (red) and nuclei staining (DAPI, blue) with confocal microscopy.

Figures 12A-F are micrographs of porcine myocardium tissue, showing the distribution of BrdU labeled cells (marked with arrows) following administration by
30 retrograde coronary venous delivery (12A-D) and by direct injection (12E-F).

Figures 13A-B show laser Doppler imaging of the mouse hindlimb, which demonstrates that the Rac $-/-$ mouse (13A) has persistent marked impairment of the ischemic leg (right leg) perfusion, whereas the wild-type mouse (13B) shows significant restoration of blood perfusion to the ischemic leg (right leg.) High or normal blood perfusion is depicted in red, and low or absent perfusion is shown in yellow and green.

- 10 Figure 14 shows the ratio of perfusion to the ischemic leg to that of the non-ischemic leg measured by laser Doppler imaging in wild-type and Rac2 $-/-$ mice.

Figures 15A-B show a representative depiction of limb necrosis on day 10 in a media injected mouse (15A) and an adipose stromal cell injected mouse (15B), which shows that adipose stromal cell injection can attenuate ischemia-induced necrosis.

- 20 Figure 16 is a graph showing that on day 10, adipose stromal cell treated animals had a significantly reduced degree of limb necrosis when compared to the control media injected mice.

DETAILED DESCRIPTION OF THE INVENTION

- Stem cells therapies are expected to someday provide a wide range of treatment options for various diseases. However the difficulties associated with obtaining stem cells in therapeutic quantities has troubled the scientific community. As described above, stem cells from blood and/or bone marrow cannot be
- 30

isolated in sufficient quantity for therapy without significant cell expansion. Further, it is difficult to find an HLA matched donor, and allogenic transplants pose a high risk of complications.

New methods of deriving stem cells from adipose tissue provide an excellent solution to these challenges. The methods disclosed herein will demonstrate that 10^5 to 10^6 cells that are obtained from 5-10 grams of subcutaneous tissue can be expanded 50-fold in approximately one week. Considering that the simple outpatient procedure of liposuction can often yield 1 liter of fat tissue even in non-obese patients, ASC cell numbers of 10^8 to 10^9 can be isolated from an individual with little or no expansion.

Furthermore, the methods disclosed herein demonstrate ways to induce these adipose stromal cells to secrete useful growth factors which can promote new tissue growth. For example, ASC's can be induced to secrete Vascular Endothelial Growth Factor (VEGF), which is known to be an effective inducer of angiogenesis.

Methods provided herein combine efficient isolation of therapeutic quantities of stem cells with inducing these stem cells to secrete growth factors such as VEGF. These cells can then be administered to a patient to promote vascularization and tissue growth in areas of ischemic damage.

I. Definitions

The following definitions are provided to facilitate an understanding of the present invention:

The term "autologous" implies identical nuclear genetic identity between donor cells or tissue and those of the recipient.

The term "adipose stromal cells" refers to the "non-adipocyte" fraction of adipose tissue. The cells can be fresh, or in culture. Adipose stromal cells contain pluripotent cells, which have the ability to differentiate into cell types including but not limited to adipocytes, cardiomyocytes, endothelial cells,
10 hematopoietic cells, hepatic cells, chondrocytes, osteoblasts, neuronal cells, and myotubes. "Adipose stem cells" are cells within the adipose stromal fraction which exhibit a stem cell phenotype, such as CD45-/Sca-1+/c-kit- or CD45-/CD34+/c-kit-.

"Therapeutic quantities of stromal cells" or "therapeutic quantities of stem cells" refers to the minimum amount of stem cells which will produce a desired therapeutic effect. For example, a therapeutic quantity of VEGF secreting stem cells is the quantity which will
20 produce therapeutically beneficial levels of angiogenesis, when administered to a patient.

"Therapeutic angiogenesis" or "therapeutic vascular growth" includes but is not limited to angiogenesis (such as capillary sprouting) and arteriogenesis (such as the maturation and enlargement of existing vessels.)

The term "regeneration" or "tissue regeneration" includes, but is not limited to the growth, generation, or reconstruction of new cells types or tissues from the ASCs of the instant invention. These cells types or
30 tissues include but are not limited to endothelial cells, cardiomyocytes, hematopoietic cells, hepatic cells, adipocytes, chondrocytes, osteoblasts, neuronal cells,

and myotubes. Cardiomyogenesis refers to cardiac tissue regeneration or reconstruction. Tissue regeneration also includes bone marrow repopulation using the ASCs of the invention, which express hematopoietic lineage cell marker(s).

"Growth factors" are molecules which promote tissue growth, cellular proliferation, vascularization, and the like. These include, but are not limited to Vascular Endothelial Growth Factors A, B, C, D, and E (VEGF),
10 Placental Growth Factor, Hepatocyte Growth Factor (HGF), Granulocyte-Colony Stimulating Factor, Granulocyte-macrophage Colony Stimulating Factor, Macrophage Colony Stimulating Factor, Monocyte Chemotactic Factor, TGF family, FGF family, pleiotrophin, endothelin, angiopoietins, and so forth.

"Multipotent" implies that a cell is capable, through its progeny, of giving rise to several different cell types found in the adult animal.

"Pluripotent" implies that a cell is capable,
20 through its progeny, of giving rise to all the cell types which comprise the adult animal including the germ cells. Both embryonic stem and embryonic germ cells are pluripotent cells under this definition.

The term "transgenic" animal or cell refers to animals or cells whose genome has been subject to technical intervention including the addition, removal, or modification of genetic information. The term "chimeric" also refers to an animal or cell whose genome has modified.

30 The term "cultured" as used herein in reference to cells can refer to one or more cells that are undergoing cell division or not undergoing cell division in an in

vitro environment. An *in vitro* environment can be any medium known in the art that is suitable for maintaining cells *in vitro*, such as suitable liquid media or agar, for example. Specific examples of suitable *in vitro* environments for cell cultures are described in Culture of Animal Cells: a manual of basic techniques (3rd edition), 1994, R. I. Freshney (ed.), Wiley-Liss, Inc.; Cells: a laboratory manual (vol. 1), 1998, D. L. Spector, R. D. Goldman, L. A. Leinwand (eds.), Cold Spring Harbor Laboratory Press; and Animal Cells: culture and media, 1994, D. C. Darling, S. J. Morgan John Wiley and Sons, Ltd.

The term "cell line" as used herein can refer to cultured cells that can be passaged at least one time without terminating. The invention relates to cell lines that can be passaged at least 1, 2, 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, and 200 times. Cell passaging is defined hereafter.

The term "suspension" as used herein can refer to cell culture conditions in which cells are not attached to a solid support. Cells proliferating in suspension can be stirred while proliferating using apparatus well known to those skilled in the art.

The term "monolayer" as used herein can refer to cells that are attached to a solid support while proliferating in suitable culture conditions. A small portion of cells proliferating in a monolayer under suitable growth conditions may be attached to cells in the monolayer but not to the solid support. Preferably less than 15% of these cells are not attached to the solid support, more preferably less than 10% of these cells are not attached to the solid support, and most

preferably less than 5% of these cells are not attached to the solid support.

The term "plated" or "plating" as used herein in reference to cells can refer to establishing cell cultures in vitro. For example, cells can be diluted in cell culture media and then added to a cell culture plate, dish, or flask. Cell culture plates are commonly known to a person of ordinary skill in the art. Cells may be plated at a variety of concentrations and/or cell
10 densities.

The term "cell plating" can also extend to the term "cell passaging." Cells of the invention can be passaged using cell culture techniques well known to those skilled in the art. The term "cell passaging" can refer to a technique that involves the steps of (1) releasing cells from a solid support or substrate and disassociation of these cells, and (2) diluting the cells in media suitable for further cell proliferation. Cell passaging may also refer to removing a portion of liquid medium containing
20 cultured cells and adding liquid medium to the original culture vessel to dilute the cells and allow further cell proliferation. In addition, cells may also be added to a new culture vessel which has been supplemented with medium suitable for further cell proliferation.

The term "proliferation" as used herein in reference to cells can refer to a group of cells that can increase in number over a period of time.

The term "permanent" or "immortalized" as used herein in reference to cells can refer to cells that may
30 undergo cell division and double in cell numbers while cultured in an in vitro environment a multiple number of times until the cells terminate. A permanent cell line

may double over 10 times before a significant number of cells terminate in culture. Preferably, a permanent cell line may double over 20 times or over 30 times before a significant number of cells terminate in culture. More preferably, a permanent cell line may double over 40 times or 50 times before a significant number of cells terminate in culture. Most preferably, a permanent cell line may double over 60 times before a significant number of cells die in culture.

10 The term "precursor cell" or "precursor cells" as used herein can refer to a cell or cells used to establish cultured mammalian cells or a cultured mammalian cell line. A precursor cell or cells may be isolated from nearly any cellular entity.

 The term "reprogramming" or "reprogrammed" as used herein can refer to materials and methods that can convert a cell into another cell having at least one differing characteristic. Also, such materials and methods may reprogram or convert a cell into another cell
20 type that is not typically expressed during the life cycle of the former cell. For example, (1) a non-totipotent cell can be reprogrammed into a totipotent cell; (2) a precursor cell can be reprogrammed into a cell having a morphology of an EG cell; and (3) a precursor cell can be reprogrammed into a totipotent cell. An example of materials and methods for converting a precursor cell into a totipotent cell having EG cell morphology is described hereafter.

 The term "isolated" as used herein can refer to a
30 cell that is mechanically separated from another group of cells. Examples of a group of cells are a developing cell mass, a cell culture, a cell line, and an animal.

The term "non-embryonic cell" as used herein can refer to a cell that is not isolated from an embryo. Non-embryonic cells can be differentiated or nondifferentiated. Non-embryonic cells can refer to nearly any somatic cell, such as cells isolated from an ex utero animal. These examples are not meant to be limiting.

The term "differentiated cell" as used herein can refer to a precursor cell that has developed from an
10 unspecialized phenotype to a specialized phenotype. For example, embryonic cells can differentiate into an epithelial cell lining the intestine. Materials and methods of the invention can reprogram differentiated cells into totipotent cells. Differentiated cells can be isolated from a fetus or a live born animal, for example.

The term "undifferentiated cell" as used herein can refer to a precursor cell that has an unspecialized phenotype and is capable of differentiating. An example of an undifferentiated cell is a stem cell.

20 The term "asynchronous population" as used herein can refer to cells that are not arrested at any one stage of the cell cycle. Many cells can progress through the cell cycle and do not arrest at any one stage, while some cells can become arrested at one stage of the cell cycle for a period of time. Some known stages of the cell cycle are G1, S, G2, and M. An asynchronous population of cells is not manipulated to synchronize into any one or predominantly into any one of these phases. Cells can be arrested in the M stage of the cell cycle, for example,
30 by utilizing multiple techniques known in the art, such as by colcemid exposure. Examples of methods for arresting cells in one stage of a cell cycle are

discussed in WO 97/07669, entitled "Quiescent Cell Populations for Nuclear Transfer".

The terms "synchronous population" and "synchronizing" as used herein can refer to a fraction of cells in a population that are within a same stage of the cell cycle. Preferably, about 50% of cells in a population of cells are arrested in one stage of the cell cycle, more preferably about 70% of cells in a population of cells are arrested in one stage of the cell cycle, and
10 most preferably about 90% of cells in a population of cells are arrested in one stage of the cell cycle. Cell cycle stage can be distinguished by relative cell size as well as by a variety of cell markers well known to a person of ordinary skill in the art. For example, cells can be distinguished by such markers by using flow cytometry techniques well known to a person of ordinary skill in the art. Alternatively, cells can be distinguished by size utilizing techniques well known to a person of ordinary skill in the art, such as by the
20 utilization of a light microscope and a micrometer, for example. In a preferred embodiment, cells are synchronized by arresting them (i.e., cells are not dividing) in a discreet stage of the cell cycle.

An "exogenous nucleic acid" as used herein refers to any nucleic acid which is introduced into the ASCs of the invention, and encodes a protein of interest. Specific exogenous nucleic acids encode proteins which include without limitation a Vascular Endothelial Growth Factor A, B, C, D, and E (VEGF), bFGF, IGF1, IGF2, Hepatocyte
30 Growth Factor (HGF), Placental Growth Factor, cardiotrophin, myotrophin, nitric oxide synthases 1,2, or 3, Granulocyte-Colony Stimulating Factor, Granulocyte-

macrophage Colony Stimulating Factor, Macrophage Colony Stimulating Factor, Monocyte Chemotactic Factor, TGF family, FGF family, pleiotrophin, endothelin, angiopoietins, and genes promoting differentiation along pre-determined pathways.

The term "modified nuclear DNA" as used herein can refer to a nuclear deoxyribonucleic acid sequence of a cell of the invention that has been manipulated by one or more recombinant DNA techniques. Examples of recombinant DNA techniques are well known to a person of ordinary skill in the art, which can include (1) inserting a DNA sequence from another organism (e.g., a human organism) into target nuclear DNA, (2) deleting one or more DNA sequences from target nuclear DNA, and (3) introducing one or more base mutations (e.g., site-directed mutations) into target nuclear DNA. Cells with modified nuclear DNA can be referred to as "transgenic cells" or "chimeric cells" for the purposes of the invention. The phrase "modified nuclear DNA" may also encompass "corrective nucleic acid sequence(s)" which replace a mutated nucleic acid molecule with a nucleic acid encoding a biologically active, phenotypically normal polypeptide. The constructs utilized to generate modified nuclear DNA may optionally comprise a reporter gene encoding a detectable product.

As used herein, the terms "reporter," "reporter system", "reporter gene," or "reporter gene product" shall mean an operative genetic system in which a nucleic acid comprises a gene that encodes a product that when expressed produces a reporter signal that is a readily measurable, e.g., by biological assay, immunoassay, radioimmunoassay, or by colorimetric, fluorogenic,

chemiluminescent or other methods. The nucleic acid may be either RNA or DNA, linear or circular, single or double stranded, antisense or sense polarity, and is operatively linked to the necessary control elements for the expression of the reporter gene product. The required control elements will vary according to the nature of the reporter system and whether the reporter gene is in the form of DNA or RNA, but may include, but not be limited to, such elements as promoters, enhancers, 10 translational control sequences, poly A addition signals, transcriptional termination signals and the like.

"Selectable marker" as used herein refers to a molecule that when expressed in cells renders those cells resistant to a selection agent. Nucleic acids encoding selectable marker may also comprise such elements as promoters, enhancers, translational control sequences, poly A addition signals, transcriptional termination signals and the like. Suitable selection agents include antibiotic such as kanamycin, neomycin, and hygromycin.

20 Methods and tools for insertion, deletion, and mutation of nuclear DNA of mammalian cells are well-known to a person of ordinary skill in the art. See, Molecular Cloning, a Laboratory Manual, 2nd Ed., 1989, Sambrook, Fritsch, and Maniatis, Cold Spring Harbor Laboratory Press; U.S. Pat. No. 5,633,067, "Method of Producing a Transgenic Bovine or Transgenic Bovine Embryo," DeBoer et al., issued May 27, 1997; and U.S. Pat. No. 5,612,205, "Homologous Recombination in Mammalian Cells," Kay et al., issued Mar. 18, 1997. These methods include 30 techniques for transfecting cells with foreign DNA fragments and the proper design of the foreign DNA

fragments such that they effect insertion, deletion, and/or mutation of the target DNA genome.

The adipose stromal cells defined herein can be altered to harbor modified nuclear or cytoplasmic DNA.

Examples of methods for modifying a target DNA genome by insertion, deletion, and/or mutation are retroviral or adeno-associated viral insertion, artificial chromosome techniques, gene insertion by electroporation, sonoporation, or chemical methods, 10 random insertion with tissue specific promoters, homologous recombination, gene targeting, transposable elements, and/or any other method for introducing foreign DNA. Other modification techniques well known to a person of ordinary skill in the art include deleting DNA sequences from a genome, and/or altering nuclear DNA sequences. Examples of techniques for altering nuclear DNA sequences are site-directed mutagenesis and polymerase chain reaction procedures. Therefore, the invention relates in part to mammalian cells that are 20 simultaneously totipotent and transgenic. Such transgenic and totipotent cells can serve as nearly unlimited sources of donor cells for production of cloned transgenic animals.

The term "recombinant product" as used herein can refer to the product produced from a DNA sequence that comprises at least a portion of the modified nuclear DNA. This product can be a peptide, a polypeptide, a protein, an enzyme, an antibody, an antibody fragment, a polypeptide that binds to a regulatory element (a term 30 described hereafter), a structural protein, an RNA molecule, and/or a ribozyme, for example. These products are well defined in the art.

The term "promoters" or "promoter" as used herein can refer to a DNA sequence that is located adjacent to a DNA sequence that encodes a recombinant product. A promoter is preferably linked operatively to an adjacent DNA sequence. A promoter typically increases an amount of recombinant product expressed from a DNA sequence as compared to an amount of the expressed recombinant product when no promoter exists. A promoter from one organism can be utilized to enhance recombinant product expression from a DNA sequence that originates from another organism. In addition, one promoter element can increase an amount of recombinant products expressed for multiple DNA sequences attached in tandem. Hence, one promoter element can enhance the expression of one or more recombinant products. Multiple promoter elements are well-known to persons of ordinary skill in the art.

The term "enhancers" or "enhancer" as used herein can refer to a DNA sequence that is located adjacent to the DNA sequence that encodes a recombinant product.

Enhancer elements are typically located upstream of a promoter element or can be located downstream of a coding DNA sequence (e.g., a DNA sequence transcribed or translated into a recombinant product or products). Hence, an enhancer element can be located 100 base pairs, 200 base pairs, or 300 or more base pairs upstream or downstream of a DNA sequence that encodes recombinant product. Enhancer elements can increase an amount of recombinant product expressed from a DNA sequence above increased expression afforded by a promoter element.

Multiple enhancer elements are readily available to persons of ordinary skill in the art.

The term "nuclear transfer" as used herein can refer to introducing a full complement of nuclear DNA from one cell to an enucleated cell. Nuclear transfer methods are well known to a person of ordinary skill in the art. See, e.g., Nagashima et al., 1997, Mol. Reprod. Dev. 48: 339-343; Nagashima et al., 1992, J. Reprod. Dev. 38: 73-78; Prather et al., 1989, Biol. Reprod. 41: 414-419; Prather et al., 1990, Exp. Zool. 255: 355-358; Saito et al., 1992, Assis. Reprod. Tech. Andro. 259: 257-266; and
10 Terlouw et al., 1992, Theriogenology 37: 309. Nuclear transfer may be accomplished by using oocytes that are not surrounded by a zona pellucida.

The terms "transfected" and "transfection" as used herein refer to methods of delivering exogenous DNA into a cell. These methods involve a variety of techniques, such as treating cells with high concentrations of salt, an electric field, liposomes, polycationic micelles, or detergent, to render a host cell outer membrane or wall permeable to nucleic acid molecules of interest. These
20 specified methods are not limiting and the invention relates to any transformation technique well known to a person of ordinary skill in the art.

The term "antibiotic" as used herein can refer to any molecule that decreases growth rates of a bacterium, yeast, fungi, mold, or other contaminants in a cell culture. Antibiotics are optional components of cell culture media. Examples of antibiotics are well known in the art. See Sigma and DIFCO catalogs.

The term "feeder cells" as used herein can refer to
30 cells that are maintained in culture and are co-cultured with target cells. Target cells can be precursor cells, adipose stromal cells, cultured cells, and totipotent

cells, for example. Feeder cells can provide, for example, peptides, polypeptides, electrical signals, organic molecules (e.g., steroids), nucleic acid molecules, growth factors (e.g., bFGF), other factors (e.g., cytokines such as LIF and steel factor), and metabolic nutrients to target cells. Certain cells may not require feeder cells for healthy growth. Feeder cells preferably grow in a mono-layer.

Feeder cells can be established from multiple cell
10 types. Examples of these cell types are fetal cells, mouse cells, and oviductal cells. These examples are not meant to be limiting. Tissue samples can be broken down to establish a feeder cell line by methods well known in the art (e.g., by using a blender). Feeder cells may originate from the same or different animal species as precursor cells. Feeder cells can be established from fetal cells, mammalian fetal cells, and murine fetal cells.

The term "receptor ligand cocktail" as used herein
20 can refer to a mixture of one or more receptor ligands. A receptor ligand can refer to any molecule that binds to a receptor protein located on the outside or the inside of a cell. Receptor ligands can be selected from molecules of the cytokine family of ligands, neurotrophin family of ligands, growth factor family of ligands, and mitogen family of ligands, all of which are well known to a person of ordinary skill in the art. Examples of
30 receptor/ligand pairs are: vascular endothelial growth factor receptor/vascular endothelial growth factor, epidermal growth factor receptor/epidermal growth factor, insulin receptor/insulin, cAMP-dependent protein kinase/cAMP, growth hormone receptor/growth hormone, and

steroid receptor/steroid. It has been shown that certain receptors exhibit cross-reactivity. For example, heterologous receptors, such as insulin-like growth factor receptor 1 (IGFR1) and insulin-like growth factor receptor 2 (IGFR2) can both bind IGF1. When a receptor ligand cocktail comprises a stimulus, the receptor ligand cocktail can be introduced to a precursor cell in a variety of manners known to a person of ordinary skill in the art.

- 10 The term "cytokine" as used herein can refer to a large family of receptor ligands well-known to a person of ordinary skill in the art. The cytokine family of receptor ligands includes such members as leukemia inhibitor factor (LIF); cardiotrophin 1 (CT-1); ciliary neurotrophic factor (CNTF); stem cell factor (SCF), which is also known as Steel factor; oncostatin M (OSM); and any member of the interleukin (IL) family, including IL-6, IL-1, and IL-12. The teachings of the invention do not require the mechanical addition of steel factor (also
- 20 known as stem cell factor in the art) for the conversion of precursor cells into totipotent cells.

II. Methods of Isolating Autologous Stem Cells from Adipose Tissues

In accordance with the present invention, it has been discovered that therapeutic quantities of autologous stem cells may be obtained from adipose tissue. Such stem cells can be obtained as described herein.

- 30 For example, adipose tissue is obtained from an animal, preferable a human, and most preferably from the patient who is the intended recipient of the therapeutic stem cells. The tissue may be obtained by numerous

methods known in the art, including without limitation liposuction, and surgery. Preferably, the adipose tissue is obtained by liposuction, which is a simple, minimally invasive procedure.

In an exemplary method, following collection, adipose tissue is optionally washed, for example with saline (such as PBS) to removed loose matter. Next, the tissue is digested with an enzyme, (such as collagenase, dispase, or trypsin), and may also be degraded by
10 mechanical agitation, sonic energy, thermal energy, and the like. The resultant product is then optionally filtered, and then centrifuged to separate the stromal cells from the adipose cells. Another round of washing and centrifugation may be performed in order to further purify the cells. The cells may also be sorted using flow cytometry or other cell sorting means, and further isolated. Cells so obtained exhibit stem cell markers, eg. CD34.

Other methods of isolating stem cells from adipose
20 tissue are known in the art, and are disclosed for example in Zuk PA, et al. *Tissue Engineering*. (2001)7:211-28.)

III. Methods of Inducing Stem Cells to Differentiate and/or Express Growth Factors

Stem cells derived from adipose tissue as set forth above may be used in many therapeutic procedures. Transgenic stem cells so obtained may also be optionally transfected at this point with a "corrective nucleic acid
30 sequence". The stem cells so obtained are then passaged and exposed to a receptor ligand cocktail to induce

differentiation into the desired cell lineage as exemplified herein below.

Tissues currently being developed from stem cells include, but are not limited to: blood vessels (Kocher, A.A. et al., Nature Med. (2001) 7:430-436; Jackson, K.A. et al., J. Clin. Invest. (2001) 107:1395-1402), bone (Petite, H. et al., Nature Biotech. (2000) 18:959-963), cartilage (Johnstone, B. et al., Clin. Orthop. (1999) S156-S162), cornea (Tsai, R.J. et al., N. Eng. J. Med. (2000) 343:86-93), dentin (Gronthos, S. et al., Proc. Natl. Acad. Sci. USA (2000) 97:13625-13620), heart muscle (Klug, M.G. et al., J. Clin. Invest. (1996) 98:216-224; review Boheler, K.R. et al., Cir. Res. (2002) 91:189-201), liver (Lagasse, E. et al., Nature Med. (2000) 6:1229-1234), pancreas (Soria, B. et al., Diabetes (2000) 49:1-6; Ramiya, V.K. et al., Nature Med. (2000) 6:278-282), nervous tissue (Bjorkland, A., Novartis Found. Symp. (2000) 231:7-15; Lee, S.H. et al., Nature Biotechnology, (2000) 18:675-679; Kim, J.H. et al., Nature (2002) 418:50-56), skeletal muscle (Gussoni, E. et al., Nature (1999) 401:390-394), and skin (Pellegrini, G. et al., Transplantation (1999) 68:868-879). Some of the tissues being generated from stem cells are described in further detail below.

Heart muscle

The loss of cardiomyocytes from adult mammalian hearts is irreversible and leads to diminished heart function. Methods have been developed in which embryonic stem (ES) cells are employed as a renewable source of donor cardiomyocytes for cardiac engraftment (Klug, M.G. et al., J. Clin. Invest. (1996) 98:216-224). The ASC

cells of the invention can be similarly differentiated.

ES cells were first transfected by electroporation with a plasmid expressing the neomycin resistance gene from an α -cardiac myosin heavy chain promoter and expressing the hygromycin resistance gene under the control of the phosphoglycerate kinase (pGK) promoter. A proportion of cells comprising an activatable α -cardiac myosin heavy chain promoter will differentiate into
10 cardiac cells. Transfected clones were selected by growth in the presence of hygromycin (200 μ g/ml; Calbiochem-Novabiochem). Transfected ES cells were maintained in the undifferentiated state by culturing in high glucose DMEM containing 10% fetal bovine serum (FBS), 1% nonessential amino acids, and 0.1 mM 2-mercaptoethanol. The medium was supplemented to a final concentration of 100 U/ml with conditioned medium containing recombinant LIF.

To induce differentiation, 2×10^6 freshly dissociated transfected ES cells were plated onto a 100-
20 mm bacterial Petri dish containing 10 ml of DMEM lacking supplemental LIF. Regions of cardiogenesis were readily identified by the presence of spontaneous contractile activity. For cardiomyocyte selection, the differentiated cultures were grown for 8 days in the presence of G418 (200 μ g/ml; GIBCO/BRL). Cultures of selected ES-derived cardiomyocytes were digested with trypsin and the resulting single cell preparation was washed three times with DMEM and directly injected into the ventricular myocardium of adult mice.

30 The culture obtained by this method after G418 selection is more 99% pure for cardiomyocytes based on immunofluorescence for myosin. The obtained

cardiomyocytes contained well defined myofibers and intercalated discs were observed to couple juxtaposed cells consistent with the observation that adjacent cells exhibit synchronous contractile activity. Importantly, the selected cardiomyocytes were capable of forming stable intercardiac grafts with the engrafted cells aligned and tightly juxtaposed with host cardiomyocytes. As mentioned previously the adipose stromal cells of the invention can be similarly treated to generate
10 cardiomyocytes.

Endothelial cells

Endothelial cells are critical to neo-vascularization, and are known to secrete numerous growth factors which promote healing and expansion. Administration of endothelial cells promotes angiogenesis, resulting in increased vascularization and development. Methods of inducing stem cells to differentiate to endothelial cells are generally known in
20 the art, and are disclosed for example, in Balconi et al., Arterioscler Thromb Vasc Biol. (2000) 20:1443-1451.

Stem cell lines were grown in the undifferentiated state either on gelatin (0.1%)-coated Petri dishes (CJ7) or on a feeder layer of STO murine fibroblasts.

To initiate cell differentiation cells were briefly trypsinized and suspended in Iscove's modified Dulbecco's medium with 15% FBS, 10 mg/mL insulin (Sigma), 100 U/mL penicillin, 100 mg/mL streptomycin, and 450 mmol/L monothioglycerol. A growth factor cocktail was added to
30 the culture medium to optimize vascular differentiation and included: recombinant human VEGF (Peprotech Inc) at 50 ng/mL; recombinant human erythropoietin (Cilag AG), at

2 U/mL; human bFGF (Genzyme), at 100 ng/mL; and murine interleukin 6 (Genzyme), at 10 ng/mL.

Cells were seeded in bacteriological Petri dishes (1.5X10⁴ cells per 35-mm Petri dish) and cultured for 11 days, without further feeding, at 37°C in an incubator with 5% CO₂ in air and 95% relative humidity. The cells were routinely examined for the presence of endothelium-like structures by whole-mount preparation, by using rat mAb MEC 7.46 directly against mouse PECAM as primary
10 antibody and commercial rabbit immunoglobulins to rat immunoglobulin (DAKO) as a secondary antibody.

In some cases, endothelial cells were selected with the use of sheep anti-mouse CD31 mAb-coated magnetic beads (Dynabeads, Dynal AS). In some experiments, endothelial cell lines could be obtained without immunoselection. In those cases, after EB disaggregation, the cells were immortalized by PmT. In previous studies, it was observed that PmT specifically immortalizes endothelial cells and not any other cell type.

20 A suitable culture medium for stem-cell derived endothelial cells is DMEM with 20% FBS, supplemented with 2 mmol/L glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, 50 mg/mL endothelial cell growth supplement (Sigma), and 100 mg/mL heparin (Sigma) (Balconi et al., Arterioscler Thromb Vasc Biol. (2000) 20:1443-1451.)

ASCs in accordance with the invention can be induced to form endothelial cells in a similar fashion.

Neuronal cells

30 Parkinson's disease is caused by the loss of midbrain neurons that synthesize the neurotransmitter dopamine. Delivery of dopamine-synthesizing neurons to

the midbrain should alleviate the symptoms of the disease by restoring dopamine production. Stem cells obtained using the methods of the invention may be differentiated into dopamine-synthesizing neurons utilizing the exemplary protocols set forth below. (Lee, S.H. et al., Nature Biotechnology, (2000) 18:675-679; Kim, J.H. et al., Nature (2002) 418:50-56).

In a murine model, mouse ES cells were first transfected by electroporation with a plasmid expressing
10 nuclear receptor related-1 (Nurr1), a transcription factor that has a role in the differentiation of midbrain precursors into dopamine neurons and a plasmid encoding neomycin resistance. Transfected clones (Nurr1 ES cells) were then subsequently isolated by culturing the cells in G418. The Nurr1 ES cells were then expanded under cultures which prevented differentiation (e.g., growth on gelatin-coated tissue culture plates in the presence of 1,400 U/ml-I of leukemia inhibitory factor (LIF; GIBCO/BRL, Grand Island, NY) in ES cell medium consisting
20 of knockout Dulbecco's minimal essential medium (GIBCO/BRL) supplemented with 15% FCS, 100 mM MEM nonessential amino acids, 0.55 mM 2-mercaptoethanol, L-glutamine, and antibiotics (all from GIBCO/BRL)). Selection of nestin-positive cells, a marker of developmental neurons, was initiated by replacing the ES cell medium by serum-free Dulbecco's modified Eagle's medium (DMEM)/F12 (1:1) supplemented with insulin (5 µg/ml), transferrin (50 µg/ml), selenium chloride (30nM), and fibronectin (5 µg/ml) (ITSFn) medium. After 6-10
30 days of selection, expansion of nestin-positive cells was initiated. Specifically, the cells were dissociated by 0.05% trypsin/0.04% EDTA, and plated on tissue culture

plastic or glass coverslips at a concentration of $1.5-2 \times 10^5$ cells/cm² in N2 medium modified (described in Johe, K. et al., Genes Dev. (1996) 10:3129-3140), and supplemented with 1 µg/ml of laminin and 10 ng/ml of bFGF (R&D Systems, Minneapolis, MN) in the presence of murine N-terminal fragment of sonic hedgehog (SHH; 500 ng/ml) and murine fibroblast growth factor (FGF) 8 isoform b (100 ng/ml; both from R&D Systems). Before cell plating, dishes and coverslips were precoated with polyornithine
10 (15 mg/ml) and laminin (1 µg/ml, both from Becton Dickinson Labware, Bedford, MA). Nestin-positive cells were again expanded for six days. The medium was changed every two days. Differentiation was induced by removal of basic FGF (bFGF). The differentiation medium consisted of N2 medium supplemented with laminin (1 mg/ml) in the presence of cAMP (1 µM) and ascorbic acid (200 µM, both from Sigma, St. Louis, MC). The cells were incubated under differentiation conditions for 6-15 days.

78% of Nurrl ES cells were found to be induced into
20 dopamine-synthesizing, tyrosine hydroxylase (TH, a rate limiting enzyme in the biosynthesis of dopamine) positive neurons by the method set forth above. The resultant neurons were further characterized to express a variety of midbrain-specific markers such as Ptx3 and Engrailed 1 (En-1). The dopamine-synthesizing, TH+ cells were also grafted into a rodent model of Parkinson's disease and were shown to extend axons, form functional synaptic connections, perform electrophysiological functions expected of neurons, innervate the striatum, and improve
30 motor asymmetry.

The ASCs of the present invention may be induced to form neuronal cells in a similar fashion.

Insulin-producing cells

An ideal treatment for diabetes is the restoration of β -cell function or mimicking the insulin secretory pattern of these cells. Insulin-secreting cells derived from stem cells have been generated by the following method and have been shown to be capable of normalizing blood glucose levels in a diabetic mouse model (Soria, B. et al., Diabetes (2000) 49:1-6).

ES cells were transfected by electroporation with a plasmid expressing β -gal under the control of the human insulin regulatory region and expressing the hygromycin resistance gene under the control of the pGK promoter. Transfected clones were selected by growth in the presence of hygromycin (200 μ g/ml; Calbiochem-Novabiochem). Transfected ES cells were maintained in the undifferentiated state by culturing in high glucose Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 1% nonessential amino acids, 0.1 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 100 IU/ml penicillin, and 0.1 mg/ml streptomycin. The medium was supplemented to a final concentration of 100 U/ml with conditioned medium containing recombinant LIF.

To induce differentiation to an insulin-secreting cell line, 2×10^6 hygromycin-resistant ES cells were plated onto a 100-mm bacterial Petri dish and cultured in DMEM lacking supplemental LIF. For ES Ins/ β -gal selection, the differentiated cultures were grown in the same medium in the presence of 200 μ g/ml G418. For final differentiation and maturation, the resulting clones were trypsinized and plated on a 100-mm bacterial Petri dish

and grown for 14 days in DMEM supplemented with 200 µg/ml G418 and 10 mM nicotinamide (Sigma), a form of Vitamin B3 that may preserve and improve beta cell function.

Finally, the resulting clusters were cultured for 5 days in RPMI 1640 media supplemented with 10% FBS, 10 mM nicotinamide, 200 µg/ml G418, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, and low glucose (5.6 mM).

For cell implantation, ES-derived insulin-secreting cells were washed and resuspended in RPMI 1640 media
10 supplemented with 10% FBS, 10 mM nicotinamide, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, and 5.6 mM glucose at 5×10^6 cells /ml. The mice to receive the implantation of ES-derived insulin-secreting cells were male Swiss albino mice that had diabetic conditions induced by a single intraperitoneal injection of streptozotocin (STZ, Sigma) at 200 mg/kg body weight in citrate buffer. 1×10^6 cells were injected into the spleen of mice under anesthesia.

The ES-derived insulin-secreting cells produced from
20 this method produced a similar profile of insulin production in response to increasing levels of glucose to that observed in mouse pancreatic islets. Significantly, implantation of the ES-derived insulin-secreting cells led to the correction of the hyperglycemia within the diabetic mouse, minimized the weight loss experienced by the mice injected with STZ, and lowered glucose levels after meal challenges and glucose challenges better than untreated diabetic mice and similar to control nondiabetic mice.

30 The ASCs of the present invention may be similarly differentiated into insulin producing cells using similar methods.

Hematopoietic Cells

Hematopoietic cells are used in numerous therapeutic regimens such as replenishing bone marrow supply, or treating hematological disorders, such as anemias, thalassemias, and so forth. Stem cells can be differentiated into hematopoietic stem cells by methods known in the art, and disclosed, for example, in Howell
10 et al., Experimental Hematology (2002) 30:915-924.

In Howell et al., CD45-Sca-1+c-kit- cells were incubated for nine days in MEM + 10% HS in the presence of 5ng/mL mSCF, mFlt-3L, and MGDF, which are cytokines. Cells were then expanded. Cells expressed increased levels of c-kit.

The *in vivo* repopulating potential of these cells was then assessed by transplanting 4×10^4 cells into lethally irradiated Boy J (CD45.1) recipient mice. Analysis of peripheral blood after 4 months revealed that
20 freshly isolated cells exhibited 7.9% +/- 2.9% chimerism in recipient mice. A mathematical derivation of fold expansion of engraftment potential of cultured cells, relative to fresh cells revealed that these cytokine cultured cells have a 5 fold increase in relative hematopoietic repopulating potential.

The ASCs of the present invention may be similarly differentiated into hematopoietic cells, and used therapeutically to treat hematopoietic disorders.

30 The recently described ability to genetically manipulate human ES cells should allow for the rapid isolation of highly uniform and singularly differentiated cells (Eiges, R. et al., Current Biol. (2001) 11:514-

518). A potential method to this end would be to employ a similar method to that described above for murine ES cells in which antibiotic resistance genes or selectable marker genes are expressed under cell specific promoters. Alternatively, cell-type specific transcription factors or any other cell-type specific factors found to drive cell-type specific differentiation can be expressed.

10 IV. Administration of Adipose Derived Stem Cells for
Therapeutic Benefit

The adipose derived stem cells of the instant invention can be used in a wide array of therapeutic procedures. These therapies include administration of adipose stem cells, administration of stem cells which secrete growth factors such as VEGF, and stem cells which have been transfected to express a desired therapeutic molecule.

20 These molecules may be administered by a variety of methods, including retrograde coronary venous delivery, direct injection, arterial infusion via catheter, systemic administration via IV, and so forth.

Methods of delivery of molecules to the heart via retrograde coronary venous delivery are generally known in the art and are described for example in Bockstegers, P et al., Gene Ther (2000) 7:232-240, Herity, NA Cathet. Cardiovasc. Intervent. (2000) 51:358-363, Suzuki et al., Circulation (2000) III:359-364, and Yock et al., US Patent 6,346,098. The injection of cells via RCVD can be at rates which achieve pressures of about 30-400 mm Hg,
30 most preferably about 50-150 mm Hg.

Retrograde coronary venous delivery is a suitable method for delivery of other types of stem cells having

therapeutic benefit. Such stem cells include without limitation bone marrow derived stem cells, peripheral blood mononuclear derived stem cells, and skeletal tissue derived myocytes.

Methods of direct injection comprise primarily direct infusion, ideally by hypodermic needle to the site where increased vascularization is desired. For example, adipose stem cells of the invention may be administered via intramuscular injection, to a tissue where
10 angiogenesis is desired.

Methods of infusion via indwelling catheter generally comprise placement of an indwelling catheter to a region where stem cell therapy would be beneficial, and administration of the adipose stem cells of the invention through such a catheter.

The following non-limiting examples are provided to further illustrate the present invention.

20 **Example 1: Isolation and Characterization of Stem Cells
From Adipose Tissue**

Isolation of Stem Cells From Adipose Tissue

To isolate adipose stromal cells (ASCs,) subcutaneous adipose tissue (5-15 grams) was obtained from obese patients undergoing a gastroplasty procedure. The tissue was suspended in PBS and dissected into smaller pieces using a scalpel. Collagenase (Worthington Biochemical) was then added to the suspension and placed
30 in a shaker at 37°C for approximately 90 minutes. The digested sample was filtered through a 750 micron Nitex filter and a 50 micron filter, and rinsed with Dulbecco's

Modified Eagle Media (DMEM) with 10% Fetal Bovine Serum (FBS). The filtered suspension was centrifuged at 200g for 5 minutes and the top layer consisting of adipocytes was discarded. After a second spin at 300g for 5 minutes, any remaining adipocytes in the top layer were again discarded. The cell pellet was re-suspended in red cell lysis buffer and centrifuged at 300g after 5-10 minutes of incubation at 37°C. This cell pellet consisted of adipose stromal cells and was re-suspended in the desired media. Adipose stromal cells (ASCs) were plated on tissue culture flasks at densities ranging from 1000 to 10,000 cells per cm². Non-adherent cells were discarded on the following day. The majority of ASCs attach to the flask and these adherent cells (Figure 1) can be expanded in either DMEM media with 10% FBS or in EGM2MV media (Clonetics), which contains the growth factors VEGF, bFGF, EGF, IGF and 5% FBS. Cells cultured in EGM2MV media, for example, can be expanded 50-fold in 8 days (Figure 2) with their growth rate decreasing when they reach confluency. ASCs continue to have a high proliferative activity when they are passaged. ASCs were also isolated from porcine and murine adipose tissue using similar isolation and culture protocols.

These experiments demonstrate that ASCs can be readily isolated and rapidly expanded *ex vivo* from relatively small amounts of adipose tissue, thus indicating that autologous ASCs may be used to advantage in research and clinical protocols. Human cardiovascular cell therapy studies suggest that 10⁸ to 10⁹ autologous cells may be required for clinical applications. Considering the fact that liposuction can yield up to 3 liters of subcutaneous fat tissue in a single outpatient

procedure, such cell numbers can be easily obtained from patients with little or no expansion.

Expression of stem cell markers on ASCs

To evaluate the expression of the stem cell marker CD-34, adipose stromal cells were freshly isolated from human adipose tissue and labeled with fluorescent antibodies against CD34 (BD Biosciences). As CD 34 is also expressed on mature endothelial cells and
10 endothelial progenitor cells, the isolated cells were co-labeled with an antibody directed against human VE-cadherin (BD Biosciences), a highly specific marker of endothelial cells (Rafii S., *J Clin Invest.* (2000)105:17-9.) Data from a representative experiment is shown in Figure 3. The results indicate that the majority of cells are CD34+/VE-cadherin-, thus suggesting that most human adipose tissue derived stromal cells are non endothelial CD34-positive stem or progenitor cells. The human adipose stromal cell fraction also contains a small
20 but distinct population of CD34+/VE-cadherin+ cells, which may represent either mature endothelial cells or endothelial progenitor cells.

To determine whether the expression of stem cell markers could also be found on adipose stromal cells in the mouse, murine ASCs were isolated from mice using the same protocol that was used for human ASC isolation. Murine ASCs were cultured, expanded in DMEM/F12 media with 10% fetal bovine serum and passaged when confluent. The passaged cells were finally detached with EDTA at
30 confluence and subsequently labeled with an antibody directed against the specific murine stem cell marker Sca-1 (Stem Cell Antigen-1). As shown in Figure 4,

greater than 70% of cultured murine ASCs express the stem cell marker Sca-1. The high level of expression of CD34 in human ASCs and of Sca-1 on murine ASCs complements the data on ASC differentiation potential (Zuk PA, et al. *Tissue Engineering*. (2001)7:211-28; Erickson et al. *Biochem Biophys Res Commun*. (2002)290:763-9; Safford KM, et al. *Biochem Biophys Res Commun*. (2002)294:371-9,) and provides evidence that ASCs have stem cell characteristics.

10

Example II: Differentiation of Adipose Derived Stromal Cells

ASCs can develop a vascular phenotype

A major pathway by which ASCs can enhance angiogenesis is by differentiation of ASCs into a vascular cell phenotype. Since ASCs are already known to differentiate into a number of cell types like muscle, bone and neural cells, it was evaluated whether ASCs can develop phenotypes that correspond to either vascular
20 endothelial cells or vascular smooth muscle cells. Plated adherent human ASCs were evaluated by flow cytometry for the expression of the stem cell marker CD34 and the endothelial marker VE-Cadherin, (Figure 5). While the majority of cells are still CD34+/VE-Cadherin, there has emerged a substantial proportion of cells that are CD34+/VE-Cadherin+; this finding has been replicated consistently with samples from several donors. This is in contrast to freshly isolated ASCs, which express minimal VE-Cadherin (Figure 3), prior to plating. The appearance
30 of a CD34+/VE-Cadherin+ cell population suggests that differentiation towards an endothelial phenotype may have occurred. This experiment also demonstrates that the

adherent ASC population continues to express high levels of the stem cell marker CD34 both in conjunction with the expression of VE-cadherin, as well as in a VE-cadherin-negative population. In parallel experiments (data not shown), it was found the human ASC population began to express an additional endothelial marker, the VEGF receptor-2, (KDR or flk-1) following passage, whereas they did not express this marker at detectable levels when freshly isolated; this finding supports the
10 interpretation of direction towards an endothelial lineage.

To examine whether ASCs can also manifest typical endothelial behavior in vitro, their phenotype on Matrigel was determined. Mature endothelial cells when plated overnight on Matrigel (BD Biosciences) form tube- and cord-like structures, reminiscent of a capillary network. Human subcutaneous ASCs that had been cultured in EGM2MV media on Matrigel overnight were plated, and the non-adherent cells were discarded the following day.
20 Human aortic endothelial cells were also plated as a positive control in a separate Matrigel well (Figure 6). The endothelial cells formed the expected tube and cord-like structures. Interestingly, ASCs also formed similar structures, further supporting the potential of ASCs to develop an endothelial phenotype.

In parallel studies designed to evaluate whether ASCs could also develop a smooth muscle phenotype, we stained ASCs cultured in DMEM/10% FBS media for the smooth muscle-specific marker, smooth muscle alpha-actin
30 (Figure 7). After culture in DMEM/10% FBS, roughly 40-50% of ASCs stain positive for alpha-actin, suggesting the development of a smooth muscle or myofibroblast

phenotype. ASCs cultured in EGM2MV show essentially no cells staining positively for SM-alpha actin.

Together, these data suggest that ASCs can develop phenotypes of specific vascular cells, in a fashion that is directly responsive to their growth factor and matrix environments, suggesting a pliability of phenotype in these cells. These data demonstrate that ASCs may be able to contribute to angiogenesis or arteriogenesis directly by providing differentiated cells for
10 incorporation into nascent vascular structures.

Example III: Secretion of Growth Factors by Adipose Derived Stromal Cells

Secretion of angiogenic growth factors by ASCs

Since stem and progenitor cells can secrete multiple growth factors (Majka M, et al. *Blood*. (2001)97:3075-85) and putative therapeutic utilities could in part be related to this endocrine function, the secretion of angiogenic growth factors by human subcutaneous ASCs was
20 evaluated. Human subcutaneous adipose stromal cells were cultured in EGM-2-MV media to confluence, and then switched into growth-factor free basal media (EBM-2, Clonetics) for 72 hours. Cell supernatants were collected and subsequently assayed for angiogenic growth factors using ELISA and Multi-Analyte-Profilng kits (R&D Systems) for Vascular Endothelial Growth Factor (VEGF), Hepatocyte Growth Factor (HGF) and Granulocyte-Colony Stimulating Factor (G-CSF). The cell number was assessed at the end of the 72-hour period, and the secretion of
30 growth factors is expressed in pg/10⁶ ASCs. The cell supernatants contained significant amounts of secreted VEGF, HGF and G-CSF (Figure 8). On the other hand,

subcutaneous ASCs did not secrete detectable levels of the arteriogenic growth factor basic FGF. These findings indicate that in addition to the pluripotency of ASCs, their endocrine or paracrine potential may have significant therapeutic relevance; ASCs delivered to the heart in the setting of coronary or peripheral arterial occlusive disease, for example, may be able enhance angiogenesis not only by differentiating into a vascular phenotype, but also by recruiting resident mature
10 vascular endothelial cells to integrate into the nascent vascular network.

**Example IV: Stromal Cells Can be Transfected with
Mammalian Plasmids and Used for Gene Therapy**

Transfection of Adipose Derived Stromal Cells with Green-
Fluorescent Protein (GFP)

ASCs are suitable host cells for transfection by mammalian expression plasmids, thus allowing for use of
20 ASCs as cellular "vectors" for gene therapy. Such transfected cells should supplement the therapeutic effects of endogenously secreted growth factors. Porcine ASCs were isolated from subcutaneous porcine adipose tissue and cultured in EGM2MV media. Confluent ASC cultures at passages 0 through 4 were suspended in PBS and electroporated with green fluorescent protein (GFP) plasmid. Optimal conditions to achieve high levels of transfection were an electroporation voltage of 300V, capacitance of 960 μ F and a cell concentration of 5×10^4 to
30 1.5×10^5 cells per μ g of DNA. Electroporated cells were plated and GFP expression was assessed on days 1-3 post transfection. Transfection efficiency as assessed by

either manual counting of GFP-positive cells (Figure 9) or by flow cytometric analysis of positive cells was routinely 50% or higher. These data show that ASCs can be transfected with non-viral methods and therefore be used as autologous cell vectors for gene therapy. This application of ASCs will be particularly beneficial in the therapeutic setting using plasmids, which encode exogenously secreted factors, which complement the activity of endogenously produced factors.

10

Example V: Further Characterization of Adipose Stromal Cells

Flow cytometric comparison of murine ASCs and muscle derived stem cells

Previous data indicated that the expression of Sca-1 on murine ASCs, and therefore suggested similarity between the subcutaneous ASC population and muscle derived Sca-1(+)CD45(-)c-kit(-) stem cells. The phenotype of murine ASCs was further defined by co-

20 staining for the markers CD45 and c-kit. As shown in Figure 10, murine ASCs contain a significant Sca-1(+)CD45(-)c-kit(-) cell population. These findings support and extend the data showing the similarity of murine ASCs and the muscle derived stem cells. This in turn provides further evidence that ASCs may have a hematopoietic potential similar to what has been shown for muscle-derived stem cells (Howell, J. et al. Exp. Hem. 30:915-24, 2002).

30

**Example VI: Further Differentiation of Adipose Derived
Stromal Cells**

Differentiation of Sca-1(+)CD45(-)c-kit(-) cells

To characterize the pluripotentiality of adipose Sca-1(+)CD45(-)c-kit(-) cells in direct comparison to that of muscle derived stem cells, Sca-1(+)CD45(-)c-kit(-) cells were purified from both tissues by cell sorting, and cultured in either neuronal or adipose
10 differentiation media. By day 12, muscle-derived Sca-1(+)CD45(-)c-kit(-) cells differentiated into adipocyte-like (with IGF-1) or neuron-like (with bFGF and PDGF) cells (Figures 11 A and B). Neuronal differentiation of these cells was confirmed by positive staining for the tau-protein (Figure 11 C.) The similarly purified population of adipose-derived Sca-1(+)CD45(-)c-kit(-) cells also responded to these respective growth conditions by differentiating into adipocyte-like (Figure 11 D) and neuron-like cells (Figure 11 E). Staining for
20 tau-protein for adipose-derived cells in neuronal differentiation media was not yet available at the time. Control experiments with Sca-1-negative cells did not demonstrate any significant transdifferentiation, thus showing for the first time that pluripotency of ASCs may be specifically observed in a particular sorted population. These data suggest that Sca-1(+)CD45(-)c-kit(-) cells within the uniquely accessible adipose tissue compartment, have comparable differentiation potential to similar cells derived from skeletal muscle,
30 and thus may represent a common stem cell in multiple tissues.

Example VII: Adipose stromal cells can be delivered to the myocardium via Retrograde Coronary Venous Delivery (RCVD) and Direct Injection

Delivery of ASCs to the Myocardium of Pigs via RCVD

Juvenile farm pigs, 25-35 kg, were used. The anterior interventricular vein (AIV) or posterior vein of left ventricle (PVLV) was cannulated by a balloon-tipped
10 catheter. The balloon was inflated to prevent venous regurgitation and myocardial blush was confirmed by 1.0-1.5 cc contrast injection.

Human adipose stromal cells, and porcine aortic endothelial cells were delivered via retrograde coronary venous delivery (RCVD.) Briefly, 5 ml of 2×10^6 pre-labeled human adipose stromal cells or porcine aortic endothelial cells were labeled with either PKH26 or BrdU, and administered to pigs. Animals were euthanized 1-1.5 hours post delivery.

20 The heart was then sliced transversely, perpendicular to the apical-basal axis. Planimetry measurement was performed using NIH Image. Cells in the area of myocardial blush were evaluated by fluorescence microscopy or immunostaining for BrdU (See figures 12A-D.)

Retrograde infusion was well tolerated in all animals without adverse hemodynamic effects; the arterial pressure and heart rate did not change significantly following delivery. The retrograde infusion time was 5.6
30 ± 2.8 sec. Non-sustained ventricular tachycardia was limited to the time of retrograde infusion, consisting of

5 to 8 ectopic beats and ceasing immediately following the injection.

As shown in figures 12A-D, PKH26 and BrdU pre-labeled cells were observed at the target myocardium tissue. From this example, it is clear that multiple cell types can be delivered into the myocardium using RCVD, and that RCVD results in widespread cell distribution in the myocardial tissue.

10 Delivery of ASCs to the Myocardium of Pigs via Direct Injection

Direct Injection of BrdU and PKH26 labeled cells was performed using a tuberculine syringe. After the heart was exposed, 200 microliters of BrdU pre-labeled cell suspension containing 2×10^5 cells was injected into the left ventricle free wall, at nine discrete injection sites. See figures 12E-F. Alternatively, cells can be injected into the ventricular muscle using needle devices
20 which are introduced from the ventricular lumen (injection into the endocardial surface), or into veins and /or arteries coursing over the heart. These techniques for intramuscular and intravascular injection are generally known in the art.

The foregoing results demonstrate that delivery of stem cells via RCVD gives rise to a wider distribution of cells in target tissue than direct microinjection.

**Example VIII: An *in vivo* Model for Assessment of
Angiogenesis**

In vivo assessment of angiogenesis using a mouse hindlimb
ischemia model

An *in vivo* model of quantifying angiogenesis over time has been established in a mouse model using hindlimb ischemia. This has allowed identification of modulators of angiogenesis. In one study, for example, the role of
10 the GTP-binding signalling molecule Rac2 was evaluated. Wild-type mice (C57BL6) and Rac2^{-/-} mice underwent ligation of the femoral artery below the inguinal ligament.

Non-invasive laser doppler imaging (LDI) (Moor Instruments) was performed on the ischemic and non-ischemic hindlimbs of all mice on post-operative days 1, 4, 7, 10, 14 and 21, in order to evaluate blood flux as a surrogate for perfusion. A representative LDI image is shown in Figure 13, where the Rac2^{-/-} mouse has
20 significant impairment of blood flow to the ischemic leg (Panel 13A), manifested by a blue shift in the colors of the pseudocolored pixels, while the wild-type mouse has recovered most of the perfusion to the ischemic leg, reflected by a bilaterally symmetric flux reflected in the pseudocolor image.

When the blood perfusion is measured over time and quantitated as a ratio of blood perfusion in the ischemic to the non-ischemic leg, it becomes apparent that the impairment in recovery of limb perfusion in Rac2^{-/-} mice
30 when compared to wild-type mice is first evident on post-surgery day 4 (Figure 14). This difference between the two groups is maintained through day 21. Statistical

analysis using a between group repeated measures ANOVA shows a highly significant between group difference. This repeated *in vivo* assessment of angiogenesis allows one to not only distinguish between global angiogenesis in a control and treatment group, but also to observe time-dependent changes. This model system can be used to quantify the effects of ASC transplantation into ischemic mouse hindlimbs on time-dependent angiogenesis.

10 Intramuscular injection of ASCs into ischemic hindlimbs improves perfusion

Human ASCs were isolated and cultured in the presence of endothelial growth media (EGM-2-MV, Clonetics) containing the growth factors VEGF, bFGF, EGF and IGF. NOD/SCID immune deficient mice (n=6, aged 8 months) underwent unilateral femoral artery ligation and received intramuscular injection of either 4×10^5 human ASCs per mouse (n=3) or media (n=3) into the quadriceps, gastrocnemius and tibialis muscles of the ischemic

20 hindlimb on the subsequent day. Due to the advanced age of the mice and the reduced immunologic competence, the endogenous angiogenesis response of the mice was markedly blunted, thus resulting in some degree of either toe or limb necrosis in all animals. However, by day 10 of the study, mice receiving ASC injections had a remarkably mitigated extent of limb necrosis (Figure 15). This reduction in necrosis was statistically significant (Figure 16).

This study highlights the *in vivo* angiogenic

30 potential of the cells. An ongoing hindlimb ischemia experiment with younger NOD/SCID mice has not resulted in any significant toe or limb necrosis, thus allowing us to

use Laser Doppler Imaging to detect subtle perfusion differences between cell-treated and media-treated animals.

The cells disclosed herein may optionally be administered by retrograde coronary venous delivery, or other means set forth above.

In conclusion, these preliminary data support the
10 hypotheses of our original proposal that ASCs have a phenotype and pluripotentiality that is similar to that of muscle-derived stem cells and that they can accordingly be used for cell therapies targeted at enhancing angiogenesis and hematopoiesis. The key advantage of identifying such cells in subcutaneous adipose tissue is that they can be harvested by liposuction and therefore increase the clinical feasibility of autologous cell therapy.

20 The previous examples and description set forth certain embodiments of the invention. It should be appreciated that not all components or method steps of a complete implementation of a practical system are necessarily illustrated or described in detail. Rather, only those components or method steps necessary for a thorough understanding of the invention have been illustrated and described in detail. Actual
implementations may utilize more steps or components or fewer steps or components. Thus, while certain of the
30 preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such

embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.

What is claimed is:

1. An isolated adipose tissue derived stromal cell.
2. The isolated cell of claim 1, which expresses at least one characteristic of a cardiac cell.
3. The isolated cell of claim 1, which expresses at
10 least one characteristic of an endothelial cell.
4. The isolated cell of claim 1, which expresses at least one characteristic of a smooth muscle cell.
5. The isolated cell of claim 1, which expresses at least one characteristic of a dopaminergic neuronal cell.
6. The isolated cell of claim 1, which expresses at
20 least one characteristic of a hepatic cell.
7. The isolated cell of claim 1 which secretes at least one factor selected from the group consisting of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), granulocyte-colony stimulating factor (G-CSF), and basic fibroblast growth factor (bFGF) .
8. The isolated cell of claim 3, cultured on matrigel.
- 30 9. The isolated cell of claim 4, cultured in DMEM and 10% fetal bovine serum which express alpha-actin.

10. The isolated cell of claim 2, cultured in the presence of 5-azacytidine.
11. The isolated cell of claim 1, which secretes a factor selected from the group consisting of pro-angiogenic factors, anti-apoptotic factors, vasculoprotective factors, and cardioprotective factors.
12. The isolated cell of claim 1, initially cultured in
10 EGM-2-MV media followed by subsequent culture in EBM-2 media, said cell secreting vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (G-CSF).
13. The isolated cell of claim 1, which expresses CD34 and does not express VE-cadherin.
14. A defined cell population comprising the cell of
20 claim 1.
15. The cell population of claim 10, wherein said cells comprise an exogenous nucleic acid encoding a protein of interest.
16. The cell population of claim 11, wherein said exogenous nucleic acid is selected from the group of nucleic acids encoding VEGF, bFGF, IGF1, IGF2, HGF, cardiotrophin, myotrophin, nitric oxide synthase 1,
30 nitric oxide synthase 2, nitric oxide synthase 3, tumor necrosis factor alpha, tumor necrosis factor beta,

fibroblast growth factor, pleiotrophin, endothelin, and angiopoietin.

17. A method for promoting angiogenesis in a mammal, comprising administration of therapeutic quantity of adipose-derived stromal cells to said mammal, such that therapeutic angiogenesis occurs.

10 18. The method of claim 17, wherein said adipose-derived stromal cells are administered via a method selected from the group consisting of retrograde coronary venous delivery, retrograde delivery into other tissues, direct microinjection into target tissue, intra-arterial infusion via a catheter, intra-coronary infusion via a catheter, and systemic intravenous administration.

19. The method of claim 17, wherein angiogenesis is promoted in cardiac tissue and said cells are
20 administered via retrograde coronary venous delivery.

20. The method of claim 19, wherein retrograde coronary venous delivery is conducted at pressures ranging from 30-400 mm Hg.

21. The method of claim 20, wherein cells so delivered enter the interstitium.

22. The method of claim 17, wherein said cells are
30 administered in a biologically compatible medium.

23. The method of claim 22, wherein said medium further comprises a viscosity-increasing carrier.

24. The method of claim 17, wherein angiogenesis is promoted in ischemic tissue.

25. A method for isolating adipose derived stromal cells from a human patient comprising:

10 a) performing adipose tissue resection or suction on said patient;

b) dissecting tissue obtained from said tissue resection or suction and dissociating said tissue into a cell suspension;

c) removing adipocytes from said cell suspension;

d) optionally exposing the cell suspension of step d) to red cell lysis buffer; and

e) isolating adipose derived stromal cells.

26. The method of claim 25, further comprising culturing the cells of step e) in a culture medium of interest.

20

27. The method of claim 26, wherein the cells of step e) are cultured in DMEM + 10% fetal bovine serum and express alpha-actin.

28. The method of claim 26, wherein the cells of step e) are initially cultured in EGM-2-MV media followed by subsequent culture in EBM-2 media, said cells secreting vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and granulocyte-colony stimulating factor (G-CSF).

30

29. The method of claim 25, further comprising introduction of an exogenous nucleic acid molecule encoding a protein of interest into the cells of step e).

30. The method of claim 26, wherein said cells are exposed to a receptor ligand cocktail, said ligands being selected from the group consisting of at least one of VEGF, LIF, bFGF, IGF1, IGF2, HGF, cardiotrophin, myotrophin, nitric oxide synthase 1, nitric oxide
10 synthase 2, nitric oxide synthase 3, tumor necrosis factor alpha, tumor necrosis factor beta, fibroblast growth factor, pleiotrophin, endothelin, and angiopoietin.

31. A method for promoting cardiomyogenesis in a mammal, comprising administration of therapeutic quantity of adipose-derived stromal cells to said mammal, such that therapeutic cardiomyogenesis occurs.

32. The method of claim 31, wherein said adipose-derived
20 stromal cells are administered via a method selected from the group consisting of retrograde coronary venous delivery, retrograde delivery into other tissues, direct microinjection into target tissue, intra-arterial infusion via a catheter, intra-coronary infusion via a catheter, and systemic intravenous administration.

33. The method of claim 31, wherein said cells are administered via retrograde coronary venous delivery.

30 34. The method of claim 33, wherein retrograde coronary venous delivery is conducted at pressures ranging from 30-400 mm Hg.

35. The method of claim 34, wherein cells so delivered enter the interstitium.

36. The method of claim 31, wherein said cells are administered in a biologically compatible medium.

37. The method of claim 31, wherein said medium further comprises a viscosity-increasing carrier.

10

38. The method of claim 31, wherein cardiomyogenesis is promoted in ischemic cardiac tissue.

39. The method of claim 31, wherein said cells further comprise an exogenous nucleic acid encoding a protein of interest.

40. A method for promoting cardiomyogenesis in a mammal, comprising retrograde coronary venous delivery of a
20 therapeutic quantity of adipose-derived stromal cells immediately following isolation of said cells, to said mammal, such that therapeutic cardiomyogenesis occurs.

41. A method for repopulating bone marrow comprising administration of therapeutic quantity of adipose-derived stromal cells to said mammal, said stem cells differentiating into cells of hematopoietic lineage, thereby repopulating bone marrow.

30 42. The method of claim 41, wherein said adipose-derived stromal cells are administered via a method selected from the group consisting of retrograde coronary venous

delivery, retrograde delivery into other tissues, direct microinjection into target tissue, intra-arterial infusion via a catheter, intra-coronary infusion via a catheter, and systemic intravenous administration.

43. The method of claim 41, wherein said cells are administered via retrograde coronary venous delivery.

44. The method of claim 43, wherein retrograde coronary
10 venous delivery is conducted at pressures ranging from 30-400 mm Hg.

45. The method of claim 41, wherein said cells are administered in a biologically compatible medium.

46. The method of claim 42, wherein said cells further comprise an exogenous nucleic acid encoding a protein of interest.

20 47. A method for promoting hematopoiesis in a mammal, comprising administration of a therapeutic quantity of adipose-derived stromal cells to said mammal, such that therapeutic hematopoiesis occurs.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6A




Figure 6B



Figure 7




Figure 8




Figure 9




Figure 10







Figure 11



Figures 12A-D



Figures 12E-F



12E



12F

Figure 13




Figure 14




Figure 15




Figure 16

